Sphera Funds Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Sphera Funds Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,595	Closed	-$236K	–	175
2021 Q1	$236K	Buy	+1,595	New	+$289K	0.02%	169
2020 Q4	–	Sell	-7,500	Closed	-$1.14M	–	133
2020 Q3	$1.14M	Hold	7,500	–	–	0.11%	85
2020 Q2	$1.32M	Buy	+7,500	New	+$1.26M	0.12%	78
2015 Q2	–	Sell	-469	Closed	-$476K	–	161
2015 Q1	$476K	Buy	+469	New	+$1.55M	0.05%	141

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's NBSE Position: Q2 2021 in Review

Sphera Funds Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2021, closing a stake of 1,595 shares — an estimated $236K sold.

Sphera Funds Management first reported a position in NBSE in Q1 2015 and held it in 4 quarters. The position peaked at $1.32M in Q2 2020. 57 funds tracked by Wall St. Rank hold NBSE as of Q2 2021.

Sphera Funds Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Sphera Funds Management sold 1,595 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $236K.
Sphera Funds Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 4 quarters.
Sphera Funds Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.32M in Q2 2020.
57 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.